Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcγRIIB), in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

NCT04219254 is registered in ClinicalTrials.gov with BioInvent International AB as lead sponsor.

NCT NCT04219254
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04219254 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcγRIIB), in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Lead sponsor
BioInvent International AB
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 29, 2020
Completion date
November 30, 2027
Enrollment
197 (estimated)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor, adult